Titan Pharmaceuticals Inc (TTNP)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

400 OYSTER POINT BLVD SAN FRANCISCO, CA 94080

Titan Pharmaceuticals is a biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system disorders. Co. is developing Probuphine for the treatment of opioid dependence. Co. has a continuous drug delivery system, which consists of a small, solid rod made from a mixture of ethylene-vinyl acetate and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the upper arm in an office procedure, and is removed in a similar manner at the end of the treatment period. Co.'s product, Fanapt (Iloperidone) is an atypical antipsychotic, for the treatment of adult patients with schizophrenia.

Data based on most recent fiscal year report
Market Cap21.2 Million Shares Outstanding21.2 Million Avg Volume220.703 Thousand
1-Yr BETA vs S&P TR1.413 Current Ratio3.67 Quick Ratio3.67
View SEC Filings from TTNP instead.
Q3 2019 All Institutions Hedge Funds 1
To trade TTNP now:
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 25 1 (0.1%)
Aggregate 13F shares on 09/30/2019: 779.183 Thousand 83.218 Thousand
Aggregate 13F shares on 06/30/2019: 861.982 Thousand 69.645 Thousand
Percent change: -9.61% 19.49%
Funds creating new positions: 5 1
Funds Adding to an existing position: 2
Funds closing out their position: 2 1
Funds reducing their position: 3
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding TTNP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SMITH SCOTT ANDREW

  • Director
24,976 2019-09-30 0

HALLBERG DANE SEE REMARKS

  • Officer
0 2019-06-05 2

BHONSLE SUNIL PRESIDENT AND CEO

  • Officer
  • Director
0 2019-04-02 1

RUBIN MARC EXECUTIVE CHAIRMAN

  • Officer
  • Director
0 2019-04-02 1

BEEBE KATHERINE CHIEF SCIENTIFIC OFFICER

  • Officer
2,387 2019-02-19 1

RECLI FEDERICO SEGHI

  • Director
800,845 2018-10-19 0

AKERS JOSEPH A

  • Director
213,000 2018-09-21 0

MCNAB JAMES R

  • Director
300,000 2018-09-21 0

MACFARLANE M DAVID

  • Director
102,275 2018-09-21 0

KUMAR RAJINDER

  • Director
0 2017-09-15 0

CAVALIER EURELIO M

  • Director
0 2017-02-16 0

BAUER VICTOR J PHD

  • Director
0 2015-12-14 0

SMITH LEY S

  • Director
0 2015-12-14 0

FARRELL ROBERT EDWARD CFO

  • Officer
333,333 2015-04-09 0

HUCKEL HUBERT E MD

  • Director
1,324,170 2014-10-02 0

BRAEBURN PHARMACEUTICALS BVBA SPRL

APPLE TREE CONSOLIDATED BVBA SPRL

APPLE TREE INVESTMENTS S.A.R.L

APPLE TREE PARTNERS IV, L.P.

ATP III GP, LTD.

HARRISON SETH LORING

  • 10% Owner
9,650,000 2013-11-25 0

KAPP JOACHIM FRIEDRICH

  • FORMER DIRECTOR
No longer subject to file 2010-10-13 0

WEIS KONRAD M PHD

  • Director
0 2008-05-30 0

BUCALO LOUIS R MD EXECUTIVE CHAIRMAN

  • Officer
  • Director
0 2008-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments